NCT00908934 - AZD9056 Relative Bioavailability Study | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2009

Study Completion Date

July 31, 2009

Conditions

Healthy

Interventions

DRUG

AZD9056 formulation Phase III 50 mg (T)

Given as 50 mg tablet (T)

DRUG

AZD9056 formulation Phase IIb 50 mg (R)

Given as 50 mg tablet (R)

DRUG

AZD9056 formulation Phase III 200 mg (T)

Given as 400 mg (2 x 200 mg tablet (T))

DRUG

AZD9056 formulation Phase IIb 200mg (R)

Given as 400 mg (2 x 200 mg tablet (R))

Trial Locations (1)

Research Site, Manchester